Abstract Background: The MelanomAIX project developed an AI-based framework to identify image-derived digital biomarkers predictive of immunotherapy response in malignant melanoma. Histopathological slides contain rich subvisual information that reflects tumor-immune interactions often missed by conventional assessment. By combining deep learning-based tissue characterization with molecular and clinical data, MelanomAIX leverages routine pathology for biomarker discovery and precision oncology. Methods: A real-world cohort of 200 melanoma patients was assembled from multiple clinical archives. Each case was curated with digitized H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1454.
Koehler et al. (Fri,) studied this question.